AAA
DYN icon

Affinity Asset Advisors’s Dyne Therapeutics DYN Stock Holding History

Affinity Asset Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100,000
Closed -$3.53M – 90
2024
Q2 		$3.53M Buy
+100,000
New +$2.91M 0.41% 50
2023
Q1 		– Sell
-92,170
Closed -$1.07M – 78
2022
Q4 		$1.07M Buy
+92,170
New +$1.07M 0.42% 50

Other funds holding DYN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Affinity Asset Advisors's DYN Position: Q3 2024 in Review

Affinity Asset Advisors sold out of Dyne Therapeutics (DYN) in Q3 2024, closing a stake of 100,000 shares — an estimated $3.53M sold.

Affinity Asset Advisors first reported a position in DYN in Q4 2022 and held it in 2 quarters. The position peaked at $3.53M in Q2 2024. 200 funds tracked by Wall St. Rank hold DYN as of Q3 2024.

  • Affinity Asset Advisors reported no remaining Dyne Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Affinity Asset Advisors sold 100,000 Dyne Therapeutics shares in Q3 2024, an estimated $3.53M.
  • Affinity Asset Advisors first reported a position in Dyne Therapeutics in Q4 2022 and held it in 2 quarters.
  • Affinity Asset Advisors's Dyne Therapeutics position peaked at $3.53M in Q2 2024.
  • 200 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2024.

Based on Affinity Asset Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.